John N. Caviness

John N. Caviness publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where John N. Caviness sits on this spectrum.

John N. Caviness D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where John N. Caviness sits on this spectrum.

Best Publications

• Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders

  Thomas G. Beach;Charles H. Adler;Lucia I. Sue;Linda Vedders

  972
  Citations

• Unified Staging System for Lewy Body Disorders: Correlation with Nigrostriatal Degeneration, Cognitive Impairment and Motor Dysfunction

  Thomas G. Beach;Charles H. Adler;LihFen F. Lue;Lucia I. Sue

  726
  Citations

• Defining mild cognitive impairment in Parkinson's disease.

  John Nathaniel Caviness;Erika M Driver-Dunckley;Donald J. Connor;Marwan N. Sabbagh

  571
  Citations

• Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study

  Charles H. Adler;Thomas G. Beach;Joseph G. Hentz;Holly A. Shill

  545
  Citations

• Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program

  Thomas G. Beach;Charles H. Adler;Lucia I. Sue;Geidy Serrano

  477
  Citations

• Myoclonus: current concepts and recent advances.

  John N Caviness;Peter Brown

  435
  Citations

• Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

  Charles H. Adler;John N. Caviness;Joseph G. Hentz;Marlene Lind

  370
  Citations

• The Montreal Cognitive Assessment and the Mini-Mental State Examination as Screening Instruments for Cognitive Impairment: Item Analyses and Threshold Scores

  Anne M. Damian;Sandra A. Jacobson;Joseph G. Hentz;Christine M. Belden

  310
  Citations

• A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor

  M. F. Brin;K. E. Lyons;J. Doucette;C. H. Adler

  289
  Citations

• Quantitative EEG as a predictive biomarker for Parkinson disease dementia

  B. T. Klassen;J. G. Hentz;H. A. Shill;Erika M Driver-Dunckley

  263
  Citations

• Pathologic findings in prospectively ascertained essential tremor subjects

  H. A. Shill;C. H. Adler;M. N. Sabbagh;D. J. Connor

  257
  Citations

• Parkinson disease with dementia: comparing patients with and without Alzheimer pathology.

  Marwan N. Sabbagh;Charles H. Adler;Tyson J. Lahti;Donald J. Connor

  257
  Citations

• Quantifying Speech Rhythm Abnormalities in the Dysarthrias

  Julie M. Liss;Laurence White;Sven L. Mattys;Kaitlin Lansford

  241
  Citations

• Higher sedentary energy expenditure in patients with Huntington's disease.

  Richard E. Pratley;Arline D. Salbe;Eric Ravussin;John N. Caviness

  210
  Citations

• Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.

  Douglas G. Walker;Lih-Fen Lue;Charles H. Adler;Holly A. Shill

  194
  Citations

• Concomitant pathologies among a spectrum of parkinsonian disorders.

  Brittany N. Dugger;Charles H. Adler;Holly A. Shill;John Caviness

  174
  Citations

• Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome.

  Yoshio Tsuboi;Keith A. Josephs;Bradley F. Boeve;Irene Litvan

  173
  Citations

• Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.

  Erika D. Driver-Dunckley;Brie N. Noble;Joseph G. Hentz;Virgilio G.H. Evidente

  170
  Citations

• Reduced striatal tyrosine hydroxylase in incidental Lewy body disease

  Thomas Gerald Beach;Charles H. Adler;Lucia I. Sue;Jeffrey B. Peirce

  168
  Citations

• Altered pharyngeal muscles in Parkinson disease.

  Liancai Mu;Stanislaw Sobotka;Stanislaw Sobotka;Jingming Chen;Hungxi Su

  164
  Citations